Summit Therapeutics Valuation

Is SMMT * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SMMT * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SMMT *'s fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SMMT *?

Key metric: As SMMT * is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SMMT *. This is calculated by dividing SMMT *'s market cap by their current book value.
What is SMMT *'s PB Ratio?
PB Ratio	31.4x
Book	US$437.92m
Market Cap	US$13.73b

SMMT * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-73.2x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SMMT *'s PB Ratio compare to its peers?

The above table shows the PB ratio for SMMT * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	3.1x
XENE Xenon Pharmaceuticals	3.8x	12.7%	US$3.0b
MRNA Moderna	1.2x	17.9%	US$14.3b
BNTX BioNTech	1.3x	12.0%	US$24.5b
RVMD Revolution Medicines	6.1x	7.2%	US$9.6b
SMMT * Summit Therapeutics	31.4x	n/a	Mex$13.7b

Price-To-Book vs Peers: SMMT * is expensive based on its Price-To-Book Ratio (31.4x) compared to the peer average (3.1x).

Price to Book Ratio vs Industry

How does SMMT *'s PB Ratio compare vs other companies in the Global Biotechs Industry?

87 Companies	Price / Book	Estimated Growth	Market Cap

87 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: SMMT * is expensive based on its Price-To-Book Ratio (31.4x) compared to the Global Biotechs industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is SMMT *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SMMT * PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	31.4x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SMMT *'s Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SMMT * forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	Mex$693.57 0%	23.7%	Mex$892.85	Mex$458.47	n/a	4
Nov ’25	Mex$374.00	Mex$723.18 +93.4%	25.4%	Mex$895.58	Mex$468.15	n/a	3
Oct ’25	n/a	Mex$714.16 0%	26.7%	Mex$900.71	Mex$452.36	n/a	3
Sep ’25	Mex$258.50	Mex$282.48 +9.3%	7.4%	Mex$309.82	Mex$258.63	n/a	3
Aug ’25	n/a	Mex$241.83 0%	2.6%	Mex$248.13	Mex$235.52	n/a	2
Jul ’25	n/a	Mex$240.00 0%	3.4%	Mex$248.27	Mex$231.73	n/a	2
Jun ’25	n/a	Mex$178.42 0%	23.8%	Mex$220.91	Mex$135.94	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV *

US$3,880.00

-11.8%

12.0%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

ROVI N

€1,416.38

54.7%

ICON

US$16.8b

A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.

ICLR N

US$4,286.08

-7.7%